OncologyOnline.net

Oncology Xagena

Some parameters of the Comprehensive Geriatric Assessment ( CGA ) are predictive of chemotherapy toxicity. The Vulnerable Elders Survey-13 ( VES-13 ) is a short instrument that has been tested as a me ...


The majority of patients with castration-resistant prostate cancer develop bone metastatic disease. It is often challenging to optimally palliate malignant bone pain. In case of multifocal pain due to ...


A study has assessed palliative selective and superselective arterial embolization with N-butyl-cyanoacrylate ( n-BCA ) for cancer patients with spinal metastases. Researchers studied the files of ...


Bone metastases are common in patients with non-small cell lung cancer ( NSCLC ), often causing pain and a decrease in quality of life ( QoL ). The effect of bone-targeted agents is evaluated by reduc ...


Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in p ...


The purpose of GORTEC 2000-01 was to compare the long-term efficacy and safety of induction chemotherapy with Cisplatin ( P ) and 5-Fluorouracil ( F ) with or without Docetaxel ( T ) for larynx preser ...


Researchers conducted a phase IIb randomized trial of preoperative chemotherapy ( CT ) plus Trastuzumab ( T ), Lapatinib ( L ), or the combination of Trastuzumab plus Lapatinib in HER2+ operable breas ...


In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary endpoint and shrank tumors ( objective response rate; ORR ) ...


Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...


In 2020 the percentage of patients with a diagnosis of cancer in people with more than 65 years will exceed 70% and 28% in ethnic minorities. The treatment of cancer in these populations is challengin ...


Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...


Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...


A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...